Instil Bio, Inc.

We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. Our wholly owned subsidiary, Axion Bio, Inc., discontinued development of AXN-2510 in January 2026. AXN-2510 was a bispecific antibody targeting programmed death-ligand 1 and vascular endothelial growth factors in solid tumor cancers, in-licensed from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in August 2024. The license and collaboration agreement with ImmuneOnco was terminated in January 2026. Previously, our development efforts focused on cell therapies, including our proprietary folate receptor alpha co-stimulatory antigen receptor (CoStAR) tumor infiltrating lymphocyte (TIL) cell therapy for cancer treatment. Our current strategy is to pursue potential acquisitions or in-licensing of therapeutic candidates. We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates for diseases with significant unmet medical need.